Your browser doesn't support javascript.
loading
Empirically defining treatment response and remission in body dysmorphic disorder.
Fernández de la Cruz, Lorena; Enander, Jesper; Rück, Christian; Wilhelm, Sabine; Phillips, Katharine A; Steketee, Gail; Sarvode Mothi, Suraj; Krebs, Georgina; Bowyer, Laura; Monzani, Benedetta; Veale, David; Mataix-Cols, David.
Afiliação
  • Fernández de la Cruz L; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden.
  • Enander J; Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.
  • Rück C; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden.
  • Wilhelm S; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden.
  • Phillips KA; Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.
  • Steketee G; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Sarvode Mothi S; New York-Presbyterian Hospital and Weill Cornell Medical College, New York, NY, USA.
  • Krebs G; Rhode Island Hospital and the Alpert Medical School of Brown University, Providence, RI, USA.
  • Bowyer L; Boston University, School of Social Work, Boston, MA, USA.
  • Monzani B; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Veale D; The National and Specialist OCD, BDD and Related Disorders Team, Child and Adolescent Mental Health Services, South London and Maudsley NHS Foundation Trust, London, UK.
  • Mataix-Cols D; MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Psychol Med ; 51(1): 83-89, 2021 01.
Article em En | MEDLINE | ID: mdl-31662124
ABSTRACT

BACKGROUND:

The number of clinical trials in body dysmorphic disorder (BDD) has steadily increased in recent years. As the number of studies grows, it is important to define the most empirically useful definitions for response and remission in order to enhance field-wide consistency and comparisons of treatment outcomes across studies. In this study, we aim to operationally define treatment response and remission in BDD.

METHOD:

We pooled data from three randomized controlled trials of cognitive-behavior therapy (CBT) for BDD (combined n = 153) conducted at four academic sites in Sweden, the USA, and England. Using signal detection methods, we examined the Yale-Brown Obsessive Compulsive Scale modified for BDD (BDD-YBOCS) score that most reliably identified patients who responded to CBT and those who achieved remission from BDD symptoms at the end of treatment.

RESULTS:

A BDD-YBOCS reduction ⩾30% was most predictive of treatment response as defined by the Clinical Global Impression (CGI) - Improvement scale (sensitivity 0.89, specificity 0.91, 91% correctly classified). At post-treatment, a BDD-YBOCS score ⩽16 was the best predictor of full or partial symptom remission (sensitivity 0.85, specificity 0.99, 97% correctly classified), defined by the CGI - Severity scale.

CONCLUSION:

Based on these results, we propose conceptual and operational definitions of response and full or partial remission in BDD. A consensus regarding these constructs will improve the interpretation and comparison of future clinical trials, as well as improve communication among researchers, clinicians, and patients. Further research is needed, especially regarding definitions of full remission, recovery, and relapse.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resultado do Tratamento / Transtornos Dismórficos Corporais / Terminologia como Assunto Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resultado do Tratamento / Transtornos Dismórficos Corporais / Terminologia como Assunto Idioma: En Ano de publicação: 2021 Tipo de documento: Article